Description
Palboxen Palbociclib 125 mg sold under the brand name Ibrance among others, is a medication developed by Pfizer for the treatment of HR-positive and HER2-negative breast cancer. This medicine is manufactured by Beacon.
Dosage & Administration: The recommended dose of Palboxen is a 125 mg capsule taken orally once daily for 21 consecutive days followed by 7 days of treatment to comprise a complete cycle of 28 days. Palboxen (Palbociclib) should be taken with food. Administer the recommended dose of an aromatase inhibitor when given with Palbonix 125 mg (Palbociclib). Please refer to the Full Prescribing Information for the aromatase inhibitor being used. When given with (Palbociclib), the recommended dose of fulvestrant is 500 mg administered on Days 1,15, 29, and once monthly thereafter. Please refer to the Full Prescribing Information of fulvestrant. Pre/perimenopausal women treated with the combination of Palboxen 125 mg (Palbociclib) plus fulvestrant therapy should be treated with luteinizing hormone-releasing hormone (LHRH) agonists according to current clinical practice standards.
Reviews
There are no reviews yet.